Gregor Zaun, Manuel Weber, Martin Metzenmacher, Marcel Wiesweg, Thomas Hilser, Yasmin Zaun, Sven Liffers, Michael Pogorzelski, Isabel Virchow, Wilfried Eberhardt, Sarah Theurer, Tanja Abu Sabbah, Timm M Reissig, Martin Stuschke, Cornelius Kürten, Timon Hussain, Stephan Lang, Stefan Kasper, Wolfgang P Fendler, Ken Herrmann, Martin Schuler
{"title":"SUV<sub>max</sub> Above 20 in <sup>18</sup>F-FDG PET/CT at Initial Diagnostic Workup Associates with Favorable Survival in Patients with Cancer of Unknown Primary.","authors":"Gregor Zaun, Manuel Weber, Martin Metzenmacher, Marcel Wiesweg, Thomas Hilser, Yasmin Zaun, Sven Liffers, Michael Pogorzelski, Isabel Virchow, Wilfried Eberhardt, Sarah Theurer, Tanja Abu Sabbah, Timm M Reissig, Martin Stuschke, Cornelius Kürten, Timon Hussain, Stephan Lang, Stefan Kasper, Wolfgang P Fendler, Ken Herrmann, Martin Schuler","doi":"10.2967/jnumed.122.265161","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer of unknown primary (CUP) is a heterogeneous entity with a limited prognosis. Novel prognostic markers are needed for patient stratification in prospective clinical trials exploring innovative therapies. <b>Methods:</b> In CUP patients treated at the West German Cancer Center Essen, the prognostic value of <sup>18</sup>F-FDG PET/CT at the initial diagnostic workup was analyzed by comparing overall survival (OS) in patients who underwent <sup>18</sup>F-FDG PET/CT with those who did not. <b>Results:</b> Of 154 patients with a CUP diagnosis, 76 underwent <sup>18</sup>F-FDG PET/CT at the initial diagnostic workup. The median overall survival (OS) of the full analysis set was 20.0 mo. Within the PET/CT subgroup, an SUV<sub>max</sub> above 20 was associated with significantly superior OS (median OS, not reached vs. 32.0 mo; hazard ratio, 0.261; 95% CI, 0.095-0.713; <i>P</i> = 0.009). <b>Conclusion:</b> Our retrospective work shows that an SUV<sub>max</sub> above 20 on <sup>18</sup>F-FDG PET/CT at the initial diagnostic workup is a favorable prognostic factor in patients with CUP. This finding deserves further prospective studies for validation.</p>","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":"64 8","pages":"1191-1194"},"PeriodicalIF":9.1000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2967/jnumed.122.265161","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Cancer of unknown primary (CUP) is a heterogeneous entity with a limited prognosis. Novel prognostic markers are needed for patient stratification in prospective clinical trials exploring innovative therapies. Methods: In CUP patients treated at the West German Cancer Center Essen, the prognostic value of 18F-FDG PET/CT at the initial diagnostic workup was analyzed by comparing overall survival (OS) in patients who underwent 18F-FDG PET/CT with those who did not. Results: Of 154 patients with a CUP diagnosis, 76 underwent 18F-FDG PET/CT at the initial diagnostic workup. The median overall survival (OS) of the full analysis set was 20.0 mo. Within the PET/CT subgroup, an SUVmax above 20 was associated with significantly superior OS (median OS, not reached vs. 32.0 mo; hazard ratio, 0.261; 95% CI, 0.095-0.713; P = 0.009). Conclusion: Our retrospective work shows that an SUVmax above 20 on 18F-FDG PET/CT at the initial diagnostic workup is a favorable prognostic factor in patients with CUP. This finding deserves further prospective studies for validation.
期刊介绍:
The Journal of Nuclear Medicine (JNM), self-published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), provides readers worldwide with clinical and basic science investigations, continuing education articles, reviews, employment opportunities, and updates on practice and research. In the 2022 Journal Citation Reports (released in June 2023), JNM ranked sixth in impact among 203 medical journals worldwide in the radiology, nuclear medicine, and medical imaging category.